Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)

NCT06841055 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT06841055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06841055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
BioNTech SE
Phase
Phase 2
Overall status
Recruiting
Start date
March 3, 2025
Completion date
October 31, 2028
Enrollment
60 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer